Segetoside I pretreatment of HepG2 resulted in apoptotic
induction, dose-dependent DNA fragmentation, inhibition of cell migration, up-regulation of Bax and
down-regulation of Bcl-2, which indicated that an apoptotic signaling event could have been initiated.
The segetoside I also suppressed hepato-tumour growth in mice with virtually no cytotoxicity and prolonged
animal survival, making it a strong oncology drug agent.